CODX

Co-Diagnostics Inc

Mar 31 • 04:00PM ET

1.86

+0.16 9.41 %

Healthcare • Medical Devices • USA • NASD

Mar 31, 8:15 PMCo-Diagnostics posts Q4 non-GAAP EPS $-16.35 on $262,500 revenue, missing EPS but beating revenue estimates, pivots FDA 510(k) to flu/RSV PCR test

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-28.73	Insider Own	8.57%	Shs Outstand	2.10M	Perf Week	-18.06%
Market Cap	3.90M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.92M	Perf Month	-19.13%
Enterprise Value	-6.07M	PEG	-	EPS next Q	-	Inst Own	8.87%	Short Float	2.97%	Perf Quarter	-72.95%
Income	-32.18M	P/S	7.65	EPS this Y	-	Inst Trans	-8.73%	Short Ratio	0.05	Perf Half Y	-83.25%
Sales	0.51M	P/B	0.07	EPS next Y	-	ROA	-54.95%	Short Interest	0.06M	Perf YTD	-63.23%
Book/sh	24.82	P/C	0.34	EPS next 5Y	-	ROE	-62.12%	52W High	46.50 -96.00%	Perf Year	-79.97%
Cash/sh	5.46	P/FCF	-	EPS past 3/5Y	- -27.40%	ROIC	-79.35%	52W Low	1.66 12.05%	Perf 3Y	-95.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-80.11% 29.07%	Gross Margin	-201.52%	Volatility	13.34% 20.70%	Perf 5Y	-99.35%
Dividend TTM	-	EV/Sales	-11.90	EPS Y/Y TTM	29.16%	Oper. Margin	-6995.70%	ATR (14)	0.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.51	Sales Y/Y TTM	-87.84%	Profit Margin	-6336.27%	RSI (14)	41.23	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.81	EPS Q/Q	51.14%	SMA20	-22.84%	Beta	1.43	Target Price	45.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-29.73%	SMA50	-24.60%	Rel Volume	0.21	Prev Close	1.70
Employees	-	LT Debt/Eq	0.02	Earnings	Mar 31 AMC	SMA200	-76.10%	Avg Volume	1.20M	Price	1.86
IPO	Jul 12, 2017	Option/Short	No / Yes	EPS/Sales Surpr.	-354.17% 108.50%	Trades		Volume	267,759	Change	9.41%

Mar-31-26 11:02PM	Co-Diagnostics Inc (CODX) Q4 2025 Earnings Call Highlights: Strategic Expansions and Financial ... (GuruFocus.com) +9.41%
04:01PM	Co-Diagnostics Reports Full Year 2025 Financial Results (PR Newswire)
Mar-25-26 08:00AM	Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization (PR Newswire) -13.22%
Mar-20-26 03:30PM	Co-Diagnostics (CODX) Expands CoSara Distribution Territory Across South Asia (NewMediaWire)

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CODX

Co-Diagnostics Inc

Upgrade your Finviz experience